Safety, Efficacy and Pharmacokinetics of BI 201335 NA in Patient With Genotype 1 Chronic Hepatitis C Virus Infection in Combination With Pegylated Interferon Alfa-2b and Ribavirin - Cohort 1 for Treatment-naive Patients: Randomised, Double-blind Part of BI 201335 NA for 12 or 24 Weeks - Cohort 2 for Treatment-experienced Patients: Open-label Part of BI 201335 NA for 24 Weeks.

Trial Profile

Safety, Efficacy and Pharmacokinetics of BI 201335 NA in Patient With Genotype 1 Chronic Hepatitis C Virus Infection in Combination With Pegylated Interferon Alfa-2b and Ribavirin - Cohort 1 for Treatment-naive Patients: Randomised, Double-blind Part of BI 201335 NA for 12 or 24 Weeks - Cohort 2 for Treatment-experienced Patients: Open-label Part of BI 201335 NA for 24 Weeks.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Faldaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top